Highest-materiality recent filing
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
Private placement of 488,281 shares and pre-funded warrants for gross proceeds of ~$2.5M at $5.12 per share (or $5.1199 for warrants).
iSpecimen effectuates 1-for-40 reverse stock split to regain Nasdaq compliance
Reverse stock split effective 4:30 p.m. ET on April 27, 2026; trading on split-adjusted basis began April 28.
iSpecimen annual meeting adjourned five times due to lack of quorum; next attempt May 8, 2026
Annual meeting convened Dec 31, 2025; quorum not present, adjourned.
iSpecimen reduces biospecimen shipping time by up to 85% with direct-to-customer model
Domestic shipments now delivered in 1-2 days vs. 7-14 days previously, a 70-85% reduction.
iSpecimen annual meeting adjourned repeatedly due to lack of quorum; next adjournment April 10, 2026
Annual meeting originally convened Dec 31, 2025; no quorum, adjourned.
Director Siyun Yang resigns from iSpecimen board effective Feb 17, 2026
Resignation not due to any disagreement with the Company on operations, policies or practices.
iSpecimen adjourns annual meeting three times due to no quorum; next attempt March 13, 2026
Dec 31, 2025 annual meeting adjourned for lack of quorum.
Milestone 2 achieved: end-to-end system integration, legacy data migration, live marketplace at mp.ispecimen.com.
iSpecimen adjourns annual meeting twice due to lack of quorum; next attempt Feb 13, 2026
Annual Meeting adjourned on Dec 31, 2025 and again on Jan 23, 2026 due to no quorum.
iSpecimen amends Series C Preferred Stock terms to add anti-dilution adjustment for reverse splits
On Jan 16, 2026, iSpecimen filed amended Certificate of Designation for Series C Convertible Non-Voting Preferred Stock.
iSpecimen pays IR Agency $2M upfront for 4-month marketing consulting
Aggregate cash fee of $2,000,000 paid upon execution from Series C Preferred Stock placement proceeds.
iSpecimen 2025 annual meeting adjourned due to lack of quorum; reconvenes Jan 23, 2026
Annual Meeting held Dec 31, 2025 adjourned because quorum was not achieved.
iSpecimen raises $5.5M via Series C Convertible Preferred Stock at $800/share
Issued 6,875 shares of Series C Convertible Non-Voting Preferred at $800/share for $5.5M aggregate.
iSpecimen regains Nasdaq compliance on stockholders' equity, matter closed
Received Nasdaq letter on Nov 28, 2025 confirming compliance with continued listing requirements.
iSpecimen receives Nasdaq deficiency notice for bid price below $1.00; cure deadline May 18, 2026
Notice received Nov 19, 2025; stock continues trading under ISPC with no immediate delisting.
Katharyn Field appointed CEO, Secretary, and Treasurer effective Nov 7, 2025; she continues as President.
Reverse stock split approved at ratio from 1:10 to 1:100; Board to set exact ratio.
iSpecimen approached by crypto companies for $200M Solana treasury initiative
iSpecimen has been approached by several crypto firms for opportunities in tokenized real-world assets and top cryptocurrencies.
iSpecimen completes Milestone 1 of digital transformation with Salestack platform
Completed Milestone 1 installation of Salestack platform and modern infrastructure for iSpecimen Marketplace.
iSpecimen plans $200M Solana-based digital asset treasury, hires BlockArrow
iSpecimen to build up to $200M corporate treasury reserve on Solana blockchain ecosystem.
iSpecimen raises $1.75M in private placement of common stock and pre-funded warrants
Gross proceeds ~$1.75M from 1,559,828 shares (or pre-funded warrants) at $1.122/share; closed August 4, 2025.
iSpecimen closes $4M public offering of common stock and pre-funded warrants
Sold 5,714,283 securities (1,482,644 shares + 4,231,639 pre-funded warrants) at $0.70/share for gross $4M.
iSpecimen amends bylaws to reduce shareholder quorum to 34% from majority
Quorum threshold reduced from a majority to 34% of voting power.
iSpecimen directors Paolone and Brooks resign; Lau appointed to board
Richard J. Paolone resigned as director and Chairman effective June 18; no disagreement involved.
Received Nasdaq letter on June 4, 2025 regarding non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
On June 20, 2025, the Board appointed Mr. Anthony Lau as a member of the Board, effective immediately, to fill one of the resulting vacancies.
On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.
On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.
Max materiality 0.75 · Median 0.55 · Most common event other_material